These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21221079)

  • 1. Boehringer splashes out on bispecific antibody platforms.
    Moran N
    Nat Biotechnol; 2011 Jan; 29(1):5-6. PubMed ID: 21221079
    [No Abstract]   [Full Text] [Related]  

  • 2. Diabodies: small bispecific antibody fragments.
    Holliger P; Winter G
    Cancer Immunol Immunother; 1997; 45(3-4):128-30. PubMed ID: 9435855
    [No Abstract]   [Full Text] [Related]  

  • 3. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
    Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
    Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant adenoviruses for in vivo expression of antibody fragments.
    Kontermann RE; Korn T; Jérôme V
    Methods Mol Biol; 2003; 207():421-33. PubMed ID: 12412489
    [No Abstract]   [Full Text] [Related]  

  • 6. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95.
    Herrmann T; Grosse-Hovest L; Otz T; Krammer PH; Rammensee HG; Jung G
    Cancer Res; 2008 Feb; 68(4):1221-7. PubMed ID: 18281499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bispecific antibodies: what future?].
    Pèlegrin A; Robert B
    Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation and characterization of bispecific tandem diabodies for tumor therapy.
    Kipriyanov SM
    Methods Mol Biol; 2003; 207():323-33. PubMed ID: 12412483
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study.
    Pfosser A; Brandl M; Salih H; Grosse-Hovest L; Jung G
    Int J Cancer; 1999 Feb; 80(4):612-6. PubMed ID: 9935165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered antibody fragments and the rise of single domains.
    Holliger P; Hudson PJ
    Nat Biotechnol; 2005 Sep; 23(9):1126-36. PubMed ID: 16151406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies: molecules that enable novel therapeutic strategies.
    Fischer N; Léger O
    Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular and cell surface displayed single-chain diabodies.
    Kontermann RE; Müller R
    J Immunol Methods; 1999 Jun; 226(1-2):179-88. PubMed ID: 10410983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of SpyTag/SpyCatcher to construct bispecific antibodies that target two epitopes of a single antigen.
    Yumura K; Akiba H; Nagatoishi S; Kusano-Arai O; Iwanari H; Hamakubo T; Tsumoto K
    J Biochem; 2017 Sep; 162(3):203-210. PubMed ID: 28637250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotechnology-2009 AAPS national conference. 21-24 June 2009, Seattle, WA, USA.
    Wu C
    IDrugs; 2009 Sep; 12(9):539-42. PubMed ID: 19697269
    [No Abstract]   [Full Text] [Related]  

  • 15. Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.
    Connelly RJ; Hayden MS; Scholler JK; Tsu TT; Dupont B; Ledbetter JA; Kanner SB
    Int Immunol; 1998 Dec; 10(12):1863-72. PubMed ID: 9885907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody fragments for controlled delivery of therapeutic agents.
    Verhoeyen ME; van der Logt CP; Beggs TS; Davis PJ
    Biochem Soc Trans; 1995 Nov; 23(4):1067-73. PubMed ID: 8654683
    [No Abstract]   [Full Text] [Related]  

  • 17. A revival of bispecific antibodies.
    Kufer P; Lutterbüse R; Baeuerle PA
    Trends Biotechnol; 2004 May; 22(5):238-44. PubMed ID: 15109810
    [No Abstract]   [Full Text] [Related]  

  • 18. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
    Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
    Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered antibodies.
    Hudson PJ; Souriau C
    Nat Med; 2003 Jan; 9(1):129-34. PubMed ID: 12514726
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody fragments: hope and hype.
    Nelson AL
    MAbs; 2010; 2(1):77-83. PubMed ID: 20093855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.